Participated · Series A · Mar 2026

Founded in 2023 by former HCA Healthcare executives, Nashville-based UnityAI develops artificial-intelligence scheduling agents that streamline operations for outpatient and specialty care providers. Its platform keeps clinical workflows moving in high-volume, rapidly changing environments, reducing administrative bottlenecks for customers such as Tennessee Oncology and Peregrine Health. The company reports that its solution is already deployed at nationwide scale, demonstrating reliable performance in real-world clinical settings. Proceeds from the latest round will be used to deepen product capabilities and expand go-to-market efforts, especially with multi-site provider platforms. UnityAI aims to move health systems beyond isolated point solutions toward integrated, AI-powered operations. Including the new capital, the startup has raised a total of $15 million to date, underscoring growing investor confidence in its approach.

Participated · Series A · Aug 2022

Abridge builds AI scribe technology that automates medical notes and integrates with Epic Systems. The company says its technology is used by over 150 of the largest U.S. health systems. In Q1 Abridge reported $117 million in contracted annual recurring revenue (a metric that includes signed recurring contracts, including customers not yet onboarded). It is expanding into converting medical notes from patient appointments into AI-powered medical codes, a move that positions it against startups like CodaMetrix and features from Epic. Abridge is widely considered a leader in the AI-powered medical scribe market due to early entry and Epic integration. The company was founded by cardiologist Shiv Rao and is seven years old. Abridge provides an enterprise-grade generative AI platform that transforms medical conversations into clinically useful and billable documentation at the point of care. The platform maps AI-generated summaries to source data using Linked Evidence to make outputs auditable and verifiable. It integrates deeply with EHRs, supports 28+ languages and 50+ specialties, and is used across outpatient, emergency department, and inpatient settings. Abridge says it has been deployed in more than 100 health systems, with enterprise implementations at Duke Health, Johns Hopkins, Mayo Clinic, UNC Health and others, representing tens of thousands of clinicians. The company recently introduced a Contextual Reasoning Engine to incorporate retrospective encounters, revenue-cycle rules, and clinician preferences to produce more comprehensive, billable notes and capture orders for EHRs. The Series D funding will support continued AI research and commercial growth to broaden applications and reduce clinician administrative burden. Abridge builds an AI-powered virtual medical scribe and clinical note-taking product that records patient encounters and generates editable visit notes. The company began with a free smartphone transcription app whose usage helped train its proprietary medical LLM on thousands of doctor–patient conversations. Its virtual scribe supports 14 foreign languages and has secured a right to be integrated inside Epic so notes can appear directly in the EHR for clinician verification. Large health systems are buying multi‑thousand-seat licenses, and Abridge has been announcing a new health system customer nearly every week since the start of 2024 (customers named include University of Chicago, Sutter, Yale, Lee Health, Christus and Emory). The company says its product materially reduces physicians’ administrative burden and has been described by customers as “life-changing” and “magical.” Abridge faces competition from incumbents and other AI scribe vendors, and observers note the open question of whether general foundation models could narrow its lead over time. Abridge builds generative AI for clinical documentation, transforming patient–clinician conversations into structured clinical notes in real time with deep EMR integrations. The platform uses Linked Evidence and auditable AI that maps AI-generated summaries to ground truth to help providers trust and verify outputs. Its stack orchestrates language identification, transcription, alignment, diarization, summarization, and verification models to produce and validate notes within seconds, reducing clinician latency from minutes to seconds. Abridge is collaborating with NVIDIA to leverage NVIDIA compute resources, foundation models, and deployment expertise to scale deployments across clinicians in the U.S. and eventually internationally. The company emphasizes research into clinically specialized foundation models, medical speech and language technology, and responsible AI. Abridge was founded in 2018 and is based in Pittsburgh, Pa. Abridge builds AI that captures and summarizes spoken patient–clinician conversations, converting them into structured clinical note drafts in real time. Its audio and ambient AI solutions integrate with EHR systems and allow patients to review notes, medication instructions, treatments, and follow-ups. The company highlights peer-reviewed R&D in medical conversation AI and user experience design. Abridge’s tools support both in-person and telemedicine appointments and aim to free clinicians from clerical work so they can focus on patients. The company says it has spent the last five years developing its technology. SCAN Group began offering Abridge’s service as a supplemental benefit in 2021.

Participated · Series B · Mar 2022

Embold Health provides real-time, transparent and actionable data on provider quality using practice-pattern and appropriateness metrics for employers, employees, health plans and health systems. Its physician-led analytics platform aligns cost and performance data with clinical guidelines across specialties including cardiology, endocrinology, gastroenterology, obstetrics, ortho-joint, pediatrics, primary care, pulmonology and spine. The tools help connect patients with top-performing providers and support engagement among physician groups, health systems, plans and employers to enable value-based care. Embold emphasizes objective, consumer-facing physician performance metrics and presents data intended to drive continuous improvement among all physicians. In a research partnership with Harvard Medical School, Embold analyzed nearly 9,000 doctors across five metropolitan areas and identified wide variations in care decisions, finding higher-performing specialists more often chose appropriate, evidence-based care. The company is using its recent financing to support national expansion and broader adoption of its quality-measurement services.